Oculis Preps for Key Data Readouts as It Eyes Neuro-Ophthalmology Leadership
Event summary
- Oculis to present at three investor conferences in March 2026, including Leerink Global Healthcare Conference on March 10.
- Privosegtor granted breakthrough therapy designation for optic neuritis, targeting $7B+ U.S. market opportunity.
- OCS-01 Phase 3 topline results for diabetic macular edema expected in Q2 2026.
- Licaminlimab in registrational trial for genotype-based dry eye disease treatment.
The big picture
Oculis is positioning itself as a leader in neuro-ophthalmology through its late-stage pipeline, with key catalysts coming in 2026. The company's focus on precision medicine and breakthrough designations could reshape treatment paradigms in optic neuropathies and dry eye disease. With a strong balance sheet and multiple data readouts approaching, Oculis aims to capture significant market share in high-value ophthalmic indications.
What we're watching
- Clinical Execution
- Whether Oculis can deliver on its six pivotal readouts with current funding.
- Market Positioning
- How Privosegtor's breakthrough designation will impact competitive dynamics in neuro-ophthalmology.
- Commercialization Timing
- The pace at which OCS-01 could become first non-invasive topical treatment for diabetic macular edema.